CRVS 10 Year Annualized Return and Average Annual Return

The CRVS 10 year annualized return is 0.57% with dividends reinvested through 07/17/2026. Investors often use annualized return to compare long-term performance because it shows the average yearly compounded return over a full period rather than just the headline total gain.

This page shows CRVS average annual return, total return, start and end dates, and the growth of a hypothetical $10,000 investment with dividends reinvested.

Quick links: Annualized Return Table  |  Performance Chart  |  FAQ
CRVS Average Annual Return Chart 10 Years
Growth of $10,000.00
Without Dividends Reinvested Into CRVS

Also see:
• CRVS stock yearly return 2017
• CRVS stock yearly return 2018
• CRVS stock yearly return 2019
• CRVS stock yearly return 2020
• CRVS stock yearly return 2021
• CRVS stock yearly return 2022
• CRVS stock yearly return 2023
• CRVS stock yearly return 2024
• CRVS stock yearly return 2025
• CRVS YTD return
Average Annual Return Benchmarks
Compare CRVS average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
CRVS Share Performance
CRVS Average Annual Return Table 10 Years
Start date: 07/20/2016
End date: 07/17/2026
Start price/share: $14.08
End price/share: $14.90
Dividends collected/share: $0.00
Total return: 5.82%
CRVS Average Annual Return: 0.57%
Starting investment: $10,000.00
Ending investment: $10,584.68
Years: 10.00


CRVS average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. The CRVS average annual return 10 years is shown above.

The Average Annual Return on the CRVS average annual return 10 years page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether CRVS average annual return 10 years or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the CRVS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
CRVS Current Stock Quote
Quotes delayed 20 minutes

Email EnvelopeFree CRVS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Featured Slideshows
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!
Video: Don't Forget Dividends in Average Annual Return!
Average Annual Return Peers
Corvus Pharmaceuticals (CRVS) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

CRY Average Annual Return
CSBR Average Annual Return
CSTL Average Annual Return
CTKB Average Annual Return
CTMX Average Annual Return
CTNM Average Annual Return
CTSO Average Annual Return
CTXR Average Annual Return
CUE Average Annual Return
CVKD Average Annual Return
More Healthcare companies »
What has the average annual return been for CRVS over the past ten years?
✔️Accepted answer: The ten year CRVS average annual return has been 0.57%.

What start date was used in your CRVS average annual return calculation?
✔️Accepted answer: The start date was 07/20/2016.

What end date was used in your CRVS average annual return calculation?
✔️Accepted answer: The end date was 07/17/2026.

If I had invested $10,000 into CRVS ten years ago, how much would I have today?
✔️Accepted answer: Today, as of 07/17/2026, you would have $10,584.68.

What does that work out to on a total return basis?
✔️Accepted answer: The CRVS ten year total return ending 07/17/2026 works out to 5.82%.


Also see:
• CRVS stock yearly return 2017
• CRVS stock yearly return 2018
• CRVS stock yearly return 2019
• CRVS stock yearly return 2020
• CRVS stock yearly return 2021
• CRVS stock yearly return 2022
• CRVS stock yearly return 2023
• CRVS stock yearly return 2024
• CRVS stock yearly return 2025
• CRVS YTD return
 

CRVS 10 Year Annualized Return & Average Annual Return | www.AverageAnnualReturn.com | Copyright © 2021 - 2026, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.